Investigation of a novel preparation of testosterone decanoate in men: Pharmacokinetics and spermatogenic suppression with etonogestrel implants

Contraception

Volumn 66, Issue 5, 2002, Pages 357-364

  Anderson, R A ^a   Zhu, H ^b   Cheng, L ^b   Baird, D T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Shanghai Institute of Family Planning Technical Instruction   (China)

Author keywords

Pharmacokinetics; Progestogen; Spermatogenesis; Testosterone

Indexed keywords

DECANOIC ACID; ETONOGESTREL; FOLLITROPIN; HEMOGLOBIN; LIVER ENZYME; LUTEINIZING HORMONE; TESTOSTERONE; 3 KETO DESOGESTREL; 3-KETO-DESOGESTREL; CHOLESTEROL; DESOGESTREL; DRUG DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALE CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; TESTOSTERONE DECANOATE; VINYL DERIVATIVE;

ADULT; ARTICLE; AZOOSPERMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG IMPLANT; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; MALE; MALE GENITAL SYSTEM; NORMAL HUMAN; SPERMATOGENESIS; WEIGHT GAIN; BLOOD; DRUG ADMINISTRATION; INJECTION; SPERMATOZOON COUNT;

ADULT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVE AGENTS, MALE; DESOGESTREL; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; HEMATOCRIT; HUMANS; INJECTIONS; MALE; PROGESTERONE CONGENERS; SPERM COUNT; SPERMATOGENESIS; TESTOSTERONE; VINYL COMPOUNDS;

EID: 0036849732     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00390-6     Document Type: Article

References (40)

1. Bhasin S., Bagatell C.J., Bremner W.J., et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab. 83:1998;3435-3448.
2. Meikle A.W., Mazer N.A., Moellmer J.F., et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 74:1992;623-628.
3. Salehian B., Wang C., Alexander G., et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men comparison to testosterone enanthate - a clinical research center study . J Clin Endocrinol Metab. 80:1995;3567-3575.
4. Wang C., Eyre D.R., Clark R., et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men a clinical research center study . J Clin Endocrinol Metab. 81:1996;3654-3662.
5. Swerdloff R.S., Wang C., Cunningham G., et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 85:2000;4500-4510.
6. Zhang G.Y., Gu Y.Q., Wang X.H., Cui Y.G., Bremner W.J. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 19:1998;761-768.
7. Nieschlag E., Büchter D., von Eckardstein S., Abshagen K., Simoni M., Behre H.M. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol. 51:1999;757-763.
8. Nieschlag E., Behre H.M. Testosterone in male contraception. Nieschlag E., Behre H.M., Testosterone: Action, deficiency, substitution. 2nd ed. 1998;513-528 Springer-Verlag, Berlin.
9. World Health Organization Task Force on Methods for the Regulation of Male Fertility . Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. Int J Androl. 18:1995;157-165.
10. World Health Organization Task Force on Methods for the Regulation of Male Fertility . Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 65:1996;821-829.
11. Zhang G.-Y., Gu Y.-Q., Wang X.-H., Cui Y.-G., Bremner W.J. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 84:1999;3642-3647.
12. Kamischke A., Venherm S., Plöger D., von Eckardstein S., Nieschlag E. Intramuscular testosterone undecanoate with norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 86:2001;303-309.
13. Anderson R.A., Kinniburgh D., Baird D.T. Suppression of spermatogenesis by etonogestrel implants with depot testosterone potential for long-acting male contraception . J Clin Endocrinol Metab. 87:2002;3640-3649.
14. th ed. 1999;Cambridge University Press, Cambridge.
15. Federal Drug Administration Working Group . Nonclinical assessment of potential hepatotoxicity in man. 2000;Federal Drug Administration.
16. Pavlou S.N., Brewer K., Farley M.G., et al. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab. 73:1991;1360-1369.
17. Bebb R.A., Anawalt B.D., Christensen R.B., Paulsen C.A., Bremner W.J., Matsumoto A.M. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone a promising male contraceptive approach . J Clin Endocrinol Metab. 81:1996;757-762.
18. Meriggiola M.C., Bremner W.J. Progestin-androgen combination regimens for male contraception. J Androl. 18:1997;240-244.
19. Wu F.C.W., Balasubramanian R., Mulders T.M.T., Coelingh-Bennink H.J.T. Oral progestogen combined with testosterone as a potential male contraceptive additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism . J Clin Endocrinol Metab. 84:1999;112-122.
20. Swerdloff R.S., Bagatell C.J., Wang C., et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotrophin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 83:1998;3527-3533.
21. Handelsman D.J., Conway A.J., Boylan L.M. Suppression of human spermatogenesis by testosterone implants. J Clin Endocrinol Metab. 75:1992;1326-1332.
22. McLachlan R.I., McDonald J., Rushford D., Robertson D.M., Garrett C., Baker H.W.G. Efficacy and acceptability of testosterone implants, alone or in combination with a 5α-reductase inhibitor, for male contraception. Contraception. 62:2000;73-78.
23. Kinniburgh D., Anderson R.A., Baird D.T. Suppression of spermatogenesis with desogestrel, and testosterone pellets is not enhanced by addition of finasteride. J Androl. 22:2001;88-95.
24. Kinniburgh D., Zhu H., Cheng L., Kicman A.T., Baird D.T., Anderson R.A. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian, and Chinese men. Hum Reprod. 17:2002;1490-1501.
25. Büchter D., von Eckardstein S., von Eckardstein A., et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab. 84:1999;1244-1249.
26. Hair W.M., Kitteridge K., O'Connor D.B., Wu F.C.W. A novel male contraceptive pill-patch combination oral desogestrel, and transdermal testosterone in the suppression of spermatogenesis in normal men . J Clin Endocrinol Metab. 86:2001;5201-5209.
27. Handelsman D.J., Wishart S., Conway A.J. Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Hum Reprod. 15:2000;672-679.
28. Anderson R.A., Wu F.C.W. Comparison between testosterone enanthate-induced azoospermia, and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once-weekly administration of testosterone enanthate. J Clin Endocrinol Metab. 81:1996;896-901.
29. Behre H.M., Nieschlag E. Comparative pharmacokinetics of testosterone esters. Nieschlag E., Behre H.M., Testosterone: action, deficiency, substitution. 1998;329-348 Springer-Verlag, Berlin.
30. Handelsman D.J., Conway A.J., Howe C.J., Turner L., Mackey M-A. Establishing the minimum effective dose, and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 81:1996;4113-4121.
31. World Health Organization Task Force on Methods for the Regulation of Male Fertility . Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 336:1990;955-959.
32. Martin C.W., Anderson R.A., Cheng L., et al. Potential impact of hormonal male contraception cross-cultural implications for development of novel preparations . Hum Reprod. 15:2000;637-645.
33. Wu F.C.W., Farley T.M.M., Peregoudov A., Waites G.M.H., WHO Task Force on Methods for the Regulation of Male Fertility . Effects of testosterone enanthate in normal men experience from a multicenter contraceptive efficacy study . Fertil Steril. 65:1996;626-636.
34. Gao E., Lin C., Gui Y., Li L., He C. Inhibiting effects of Sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reprod Contracept. 10:1999;98-105.
35. Bhasin S., Woodhouse L., Casaburi R., et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 281:2001;E1172-E1181.
36. Mirand E.A., Gordon A.W., Wenig J. Mechanism of testosterone action in erythropoiesis. Nature. 206:1965;270-272.
37. Anderson R.A., Ludlam C.A., Wu F.C.W. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost. 74:1995;693-697.
38. Meriggiola M.C., Bremner W.J., Paulsen C.A., et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab. 81:1996;3018-3023.
39. Wallace E.M., Wu F.C.W. Effect of depot medroxyprogesterone acetate, and testosterone oenanthate on serum lipoproteins in man. Contraception. 41:1990;63-71.
40. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic, and behavioural effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 79:1994;561-567.